Metadata record for the manuscript: Tumor-associated autoantibodies from mouse breast cancer models are found in serum of breast cancer patients
Creators: name: Stanton, Sasha E.
name: Ekram Gad
name: Ramos, Erik
name: Corulli, Lauren
name: Annis, James
name: Childs, Jennifer
name: Katayama, Hiroyuki
name: Hanash, Samir
name: Marks, Jeffrey
name: Disis, Mary L.
Publisher: name: figshare
Year: 2021
Subjects: subject: Cancer
subject: 69999 Biological Sciences not elsewhere classified
subject: FOS: Biological sciences
subject: FOS: Biological sciences
subject: Biomarkers

description: <b>Summary</b><br> This metadata record provides details of the data supporting the claims of the related manuscript: “Tumor-associated autoantibodies from mouse breast cancer models are found in serum of breast cancer patients”. The related study aimed to identify tumour antigens from autoantibodies identified prior to palpable tumours in two mouse mammary tumour models (TgMMTV-neu and C3(1)Tag) that were involved in survival of HER2 positive and triple negative human breast cancer cell lines as they could be effective immunogens in breast cancer vaccines. Type of data: tumour growth under vaccination with antigen-specific epitopes Subject of data: <i>Homo sapiens; </i>Eukaryotic cell lines; <i>Mus musculus</i> Sample size: For the mouse studies comparing adjuvant immunized mice to antigen vaccinated, eight animals per group was used to provide 95% power to observe a statistically significant difference in tumor size between antigen vaccinated mice as compared to control vaccinated mice (at the two-sided level of α=0.05) if the effect size is 2.0. For the human samples, screening 30 DCIS cases with 30 matched controls gives a 90% power to detect a 2-fold difference in candidate antigen specific IgG (µg/ml) between control and DCIS patients as calculated by the observed distribution of IgG response in a previous antigen (IGF-IR) in breast cancer (Cecil Breast Cancer Res Treat 139:657) Population characteristics: The serum from control women (n=43) were acquired from volunteers from the Puget Sound Blood Center and serum from women with invasive breast cancer (n=37) were acquired from the Cancer Vaccine Institute specimen repository and were collected using the same methods (table 3). The serum for benign, fibroadenoma, hyperplasia, and DCIS were obtained from a Duke repository with blood drawn at the time of an abnormal mammogram and in patients with no invasive pathology at surgery. The definition of a benign lesion was defined as radial scar, cyst, and no fibroadenoma or atypia. The Duke Repository serum was from women with benign tumors (n=12), fibroadenoma (n=37), hyperplasia (n=12), and DCIS (n=59). <b>Data access</b> The data underlying the related study are contained in Excel spreadsheets in the files ‘NPJ to make volcano.xlsx’ and ‘NPJ Figures.xlsx’. These files are not openly available in a repository as they contain additional data that were not included in the related study. However, the files are available upon request by email to the corresponding author. <b>Corresponding author(s) for this study</b> Sasha E. Stanton, Earle A. Chiles Research Institute, 4805 NE Glisan Street 2N103, Portland, OR 97213, sasha.stanton@providence.org <br> <b>Study approval </b> All patients were consented prior to blood collection at the institution where the samples were obtained. However, because all the samples were de-identified before the investigators for this study received them, they were IRB exempt as determined by the University of Washington institutional review board.